From our Industry Experts

TMCNet:  Research and Markets: CVT-301 (Parkinson's Disease) by Civitas Therapeutics- Forecast and Market Analysis to 2022

[May 19, 2014]

Research and Markets: CVT-301 (Parkinson's Disease) by Civitas Therapeutics- Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/vltc4s/cvt301) has announced the addition of the "CVT-301 (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering.

CVT-301 has been developed by Civitas Therapeutics as the company's leading candidate for the treatment of OFF episodes in Parkinson's disease. Using the ARCUS inhaler platform, levodopa is inhaled into the lung where it is delivered to the blood, avoiding the gastrointestinal tract and producing more rapid effects than orally administered levodopa. CVT-301 will be taken as needed, similar to a rescue inhler, which is common in the asthma market. It will not replace the patient's current oral doses of levodopa or other medications, but will be taken in addition to them.




Scope

  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on CVT-301 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for CVT-301 for the top six countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of CVT-301 performance
  • Obtain sales forecast for CVT-301 from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

For more information visit http://www.researchandmarkets.com/research/vltc4s/cvt301


[ Back To Real Time Communications's Homepage ]

Home




  Subscribe here for RTCW eNews   Upcoming Webinars


Featured Videos

Kandy Wrapper: Visual Attendant
Kandy Visual Attendant is ready for resale. The turnkey solution can be custom branded ...

NFV Made Easy
Moving to an NFV gives you An agile and lower cost network. With GENBAND's NFV Solutions ...
Kandy Bus 2016 Connected Experience
Kandy presents A Connected Experience, a three-part fire-starter where we build entire Kandy-enabled ...

View All